Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials

Executive Summary

UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.

Advertisement

Related Content

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Big Pharma Presence In Gene Therapy Dealmaking Validates Technology
Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
A Cellectis Trial Death Points To Challenges Ahead For CAR-T
Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
CAR-T Companies Hang Onto Novartis' Coat-Tails After Historic FDA Panel Vote
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite
AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel